Venous thromboembolism in metastatic urothelial carcinoma or variant histologies: incidence, associative factors, and effect on survival

Jorge D. Ramos1, a, Martin F. Casey2, a, Simon J. Crabb3, Aristotelis Bamias4, Lauren C. Harshman5, Yu-Ning Wong6, Joaquim Bellmunt7, Ugo De Giorgi8, Sylvain Ladoire9,10, Thomas Powles11, Sumanta K. Pal12, Guenter Niegisch13, Federica Recine8, Ajjai Alva14, Neeraj Agarwal15, Andrea Necchi16, Ulka N. Vaishampayan17, Jonathan E. Rosenberg18, Matthew D. Galsky2, Evan Y. Yu1 & RISC Investigators

1University of Washington, Seattle, Washington
2Icahn School of Medicine at Mount Sinai, New York, New York
3University of Southampton, Southampton, England
4National and Kapodistrian University of Athens, Athens, Greece
5Dana Farber Cancer Institute, Boston, Massachusetts
6Fox Chase Cancer Center, Philadelphia, Pennsylvania
7Hospital del Mar, Barcelona, Spain
8Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy
9Georges François Leclerc Center, Dijon, France
10Université de Bourgogne, Dijon, France
11Barts and the London School of Medicine, London, England
12City of Hope, Duarte, California
13Heinrich-Heine-University, Düsseldorf, Germany
14University of Michigan, Ann Arbor, Michigan
15University of Utah, Salt Lake City, Utah
16Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy
17Karmanos Cancer Institute, Detroit, Michigan
18Memorial Sloan Kettering Cancer Center, New York, New York

© 2016 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Keywords
Urothelial, bladder cancer, chemotherapy, survival, venous thromboembolism

Abstract
Venous thromboembolism (VTE) is common in cancer patients. However, little is known about VTE risk in metastatic urothelial carcinoma or variant histologies (UC/VH). We sought to characterize the incidence, associative factors, including whether various chemotherapy regimens portend different risk, and impact of VTE on survival in metastatic UC/VH patients. Patients diagnosed with metastatic UC/VH from 2000 to 2013 were included in this multicenter retrospective, international study from 29 academic institutions. Cumulative and 6-month VTE incidence rates were determined. The association of first-line chemotherapy (divided into six groups) and other baseline characteristics on VTE were analyzed. Each chemotherapy treatment group and statistically significant baseline clinical characteristics were assessed in a multivariate, competing-risk regression model. VTE patients were matched to non-VTE patients to determine the impact of VTE on overall survival. In all, 1762 patients were eligible for analysis. There were 144 (8.2%) and 90 (5.1%) events cumulative and within the first 6 months, respectively. VTE rates based on chemotherapy group demonstrated no statistical difference when gemcitabine/cisplatin was used as the comparator. Non-urothelial histology (SHR: 2.67; 95% CI: 1.72–4.16, \( P < 0.001 \)) and cardiovascular disease (CVD) or CVD risk factors (SHR: 2.27; 95% CI: 1.49–3.45, \( P = 0.001 \))
were associated with increased VTE rates. Overall survival was worse in patients with VTE (median 6.0 m vs. 10.2 m, \( P < 0.001 \)). Thus, in metastatic UC/VH patients, VTE is common and has a negative impact on survival. We identified multiple associated potential risk factors, although different chemotherapy regimens did not alter risk.

**Introduction**

Cancer patients are at increased risk of developing a venous thromboembolism (VTE). It is now estimated that approximately 20–30% of first VTE in patients are cancer associated [1]. Improved survival outcomes across multiple malignancies, increasing use of central venous catheters, and better imaging modalities to detect venous thrombosis have led to a rising incidence of cancer-associated thrombosis over time [2]. Importantly, VTEs have been shown to have a negative impact on survival [3]. In addition, cancer patients with a VTE have increased morbidity from anticoagulation, with a higher risk of recurrent VTE and major bleeding compared to noncancer patients with VTE [4].

Patient-related characteristics such as a high body mass index (BMI), elevated white blood cell (WBC) and platelet count, and low hemoglobin have been incorporated into the Khorana score, a validated, predictive model of VTE risk in patients who are initiating chemotherapy [5]. When looking at specific cancer primary sites, the most aggressive malignancies, such as pancreatic cancer, have tended to have the greatest VTE risk [6]. Finally, there is a mounting body of evidence for chemotherapy as an independent risk factor for VTE, with the strongest data for cisplatin [7–9]. Moreover, some studies have indicated especially high thromboembolic rates (arterial and venous) in patients treated with the combination of gemcitabine and cisplatin (GC) [7, 10–12].

Despite the growing amount of data on cancer-associated thrombosis, there is limited literature assessing the incidence and risk factors for VTEs in urothelial carcinoma or variant histologies (UC/VH), especially in the metastatic setting. Additionally, UC/VH have been underrepresented in previous VTE studies. In the patient cohort utilized to develop the Khorana score, genitourinary malignancies (excluding prostate cancer) were grouped with other primary tumor sites which only represented approximately 10% of the study population, yet they are still considered a high-risk primary tumor site and given 1 point in the model [5]. Likewise, in the largest randomized, prospective clinical trial assessing primary thromboprophylaxis across multiple solid tumors, bladder cancer only accounted for 2% of the patient population [13]. Given the dearth of information on VTE in patients with metastatic UC/VH, we conducted a retrospective cohort study to better understand the incidence and risk factors associated with VTE, whether chemotherapy (in particular the combination of GC) increases VTE risk, and the impact of VTE on survival.

**Methods**

**Study design and patient population**

The Retrospective International Study of Cancers of the Urothelium (RISC) is a multicenter study of the management and outcomes of patients with cancers of the urothelial tract with at least muscle-invasive disease (clinical T-classification of ≥2). Baseline characteristics, laboratory, pathology, treatment, and outcome data were collected and compiled via a secure, password-protected electronic data capture platform from 29 international centers as previously described [14]. The study was approved by the institutional review board at all participating institutions.

Patients diagnosed with metastatic disease of the bladder, renal pelvis, ureter, and urethra from 1 January 2000 through 31 December 2013 were eligible for analysis. Urothelial, adenocarcinoma, micropapillary, sarcomatoid, small cell, and squamous histologies were included for analysis. In patients with mixed histology tumors, the predominant histologic pattern of the tumor was utilized for categorization. Patients without a known date of diagnosis, date of last follow-up, or VTE data were excluded from the study. First-line chemotherapy regimens were subdivided into six groups for analysis: (1) GC, (2) gemcitabine and carboplatin, (3) cisplatin combination (excluding GC), (4) nonplatinum regimens, (5) carboplatin or oxaliplatin (excluding gemcitabine and carboplatin), and (6) no chemotherapy. Specific chemotherapy regimens within the chemotherapy subgroups are listed in supplementary Table 1. Based on previous data suggesting particularly high rates of thromboembolic events with GC, we hypothesized that there would be more VTEs in this treatment group when compared to other treatment groups. Additionally, GC is a commonly used regimen for advanced disease, therefore, GC was chosen as the reference for comparison to the other chemotherapy treatment groups [15]. Other baseline patient, tumor, and treatment-related
characteristics were assessed for their impact on VTE incidence (see full list in Table S2).

Statistical analysis

Cumulative and 6-month absolute VTE incidence rates were calculated from the date of diagnosis of metastatic disease to the VTE date. Each baseline and treatment-related factor was assessed, using competing-risk regressions, for association with the development of VTE. Multiple imputations with chained equations were performed to address any missing data. First-line chemotherapy group and any statistically significant covariates in the univariate analysis ($P \leq 0.05$) were evaluated in a multivariate, competing-risk regression model. Subdistribution hazard ratios (SHR) were calculated for each factor.

To assess survival, a nested case–control analysis was performed where VTE patients (cases) were matched to non-VTE patients (controls). Cases and controls were matched based on time from date of diagnosis of metastatic disease to date of VTE diagnosis of the case, age, gender, race, and whether the patient received chemotherapy. Patients were also matched based on ECOG performance status and presence of liver metastases as these factors have been previously demonstrated to be poor prognostic features in patients with bladder cancer [16]. All attempts were made to match five controls to one case, however, because of the number of variables utilized, 5:1 matching could not be achieved for all strata. In those cases, the highest degree of matching possible was employed. Overall survival was calculated from the time of the VTE event. The log-rank test was utilized to compare survival between cases and controls. All statistical analyses were performed using Stata 13/IC 13.1.

Results

Study population and patient characteristics

The RISC database is comprised of 3025 patients. In all, 1912 patients were diagnosed with metastatic disease (Fig. 1). Of these, 65 patients were diagnosed prior to 1 January 2000 and thus excluded from the analysis. An additional 85 patients were excluded due to missing or miscoded date of diagnosis, last follow-up, or VTE data to arrive at a final cohort of 1762 patients eligible for

---

**Table 1. Patient characteristics.**

|                | N (%)   |
|----------------|---------|
| Total          | 1762 (100) |
| Age            |         |
| <40            | 15 (0.9)   |
| 40–64          | 683 (38.8) |
| >65            | 1039 (59.0) |
| Unknown        | 25 (1.4)   |
| Gender         |         |
| Male           | 1365 (77.5) |
| Female         | 390 (22.1)  |
| Unknown        | 7 (0.4)    |
| Race           |         |
| White          | 1595 (90.5) |
| Other          | 157 (8.9)   |
| Unknown        | 10 (0.6)    |
| Primary tumor location |    |
| Bladder        | 1462 (83.0) |
| Other (renal pelvis, ureter, or urethra) | 265 (15.0) |
| Unknown        | 35 (2.0)    |
| Histology      |         |
| Urothelial     | 1525 (86.5) |
| Non-urothelial | 183 (10.4)  |
| Unknown        | 54 (3.1)    |
| Primary treatment |   |
| Surgery$^1$    | 593 (33.7)  |
| Surgery$^1$ with perioperative chemotherapy | 422 (24.0)  |
| Radiation      | 117 (6.6)   |
| Radiation with concurrent chemotherapy | 89 (5.1)    |
| None/Unknown   | 541 (30.7)  |

$^1$Encompasses patients who underwent a radical cystectomy, nephroureterectomy, nephrectomy, ureterectomy, or urethrectomy as their primary treatment modality.
Table 2. Unadjusted incidence rates of venous thromboembolic events by clinical characteristics. 8

| VTE/N   | Incidence rate (95% CI) | Absolute rate (95% CI) | P-value |
|---------|-------------------------|-------------------------|---------|
| Total   | 144/1762                | 7.5 (6.4–8.8)           | 8.2 (6.9–9.6) | -- |
| Age     |                         |                         |         |
| <40     | 1/15                    | 3.6 (0.5–25.7)          | 6.7 (0.2–31.9) | 0.10³ |
| 40–64   | 65/683                  | 8.0 (6.3–10.2)          | 9.5 (7.4–12.0) |       |
| >65     | 77/1039                 | 7.3 (5.8–9.1)           | 7.4 (5.9–9.2) |       |
| Unknown | 1/25                    | 4.2 (0.6–30.1)          | 4.0 (0.1–20.4) |       |
| Gender  |                         |                         |         |
| Male    | 108/1365                | 7.2 (6.0–8.7)           | 7.9 (6.5–9.5) | 0.23   |
| Female  | 36/390                  | 8.8 (6.4–12.2)          | 9.2 (6.5–12.6) | Ref    |
| Unknown | 0/7                     | 0.0 (…)                 | 0.0 (0.0–41.0) | --     |
| Race    |                         |                         |         |
| White   | 127/1595                | 7.2 (6.1–8.6)           | 8.0 (6.7–9.4) | Ref    |
| Other   | 15/142                  | 9.7 (5.8–16.1)          | 9.6 (5.4–15.3) | 0.20   |
| Unknown | 2/10                    | 18.1 (4.5–72.4)         | 20.2 (2.5–55.6) |       |
| Leukocyte count (μL) |             |                         |         |
| ≤11,000 | 93/949                  | 7.7 (6.3–9.4)           | 9.8 (8.0–11.9) | Ref    |
| >11,000 | 21/222                  | 9.9 (6.5–15.2)          | 9.5 (6.0–14.1) | 0.61   |
| Unknown | 30/591                  | 6.1 (4.2–8.7)           | 5.1 (3.5–7.2) | --     |
| Platelet count (μL) |             |                         |         |
| <350,000| 78/804                  | 7.6 (6.1–9.4)           | 9.7 (7.7–12.0) | Ref    |
| ≥350,000| 36/352                  | 9.8 (7.0–13.5)          | 10.2 (7.3–13.9) | 0.62   |
| Unknown | 30/606                  | 5.8 (4.0–8.3)           | 5.0 (3.4–7.0) | --     |
| Hemoglobin (g/dL) |             |                         |         |
| <10     | 20/171                  | 13.5 (8.7–21.0)         | 11.7 (7.3–17.5) | 0.37   |
| ≥10     | 95/984                  | 7.6 (6.3–9.3)           | 9.7 (7.9–11.7) | Ref    |
| Unknown | 29/607                  | 5.5 (3.8–7.9)           | 4.8 (3.2–6.8) | --     |
| Body mass index |             |                         |         |
| <35     | 99/907                  | 9.4 (7.7–11.4)          | 10.9 (9.0–13.1) | Ref    |
| ≥35     | 6/56                    | 6.1 (2.8–13.7)          | 10.7 (4.0–21.9) | 0.99   |
| Unknown | 39/799                  | 5.1 (3.7–7.0)           | 4.9 (3.5–6.6) | --     |
| CVD or CVD risk factors³ |           |                         |         |
| No      | 48/794                  | 4.8 (3.6–6.4)           | 6.0 (4.5–7.9) | Ref    |
| Yes     | 96/968                  | 10.4 (8.5–12.7)         | 9.9 (8.1–12.0) | <0.001 |
| Moderate to severe renal dysfunction⁶ |     |                         |         |
| No      | 122/1605                | 6.9 (5.8–8.2)           | 7.6 (6.4–9.0) | Ref    |
| Yes     | 22/157                  | 14.6 (9.6–22.2)         | 14.0 (9.0–20.4) | 0.001  |
| ECOG performance status |             |                         |         |
| 0       | 29/345                  | 5.2 (3.6–7.6)           | 8.4 (5.7–11.8) | Ref    |
| 1       | 63/526                  | 9.9 (7.8–12.7)          | 12.9 (9.3–15.1) | 0.22   |
| 2+      | 16/193                  | 11.9 (7.3–19.5)         | 8.3 (4.8–13.1) | 0.78   |
| Unknown | 36/698                  | 6.0 (4.3–8.3)           | 5.2 (3.6–7.1) | --     |
| Primary tumor location |          |                         |         |
| Bladder | 121/1462                | 7.9 (6.6–9.4)           | 8.3 (6.9–9.8) | Ref    |
| Other (renal pelvis, ureter, or urethra) | 21/265 | 6.1 (4.0–9.3) | 7.9 (5.0–11.9) | 0.58 |
| Unknown | 2/35                    | 6.2 (1.5–24.7)          | 5.7 (0.7–19.2) | --     |
| Histology |                     |                         |         |
| Urothelial | 105/1525              | 6.2 (5.1–7.5)           | 6.9 (5.7–8.3) | Ref    |
| Non-urothelial | 34/183             | 18.9 (13.5–26.5)        | 18.6 (13.2–25.0) | <0.001 |
| Unknown  | 5/54                    | 12.3 (5.1–29.7)         | 9.3 (3.1–20.3) | --     |
| Liver metastases |             |                         |         |
| No      | 119/1421                | 7.3 (6.1–8.7)           | 8.4 (7.0–9.9) | Ref    |
| Yes     | 24/324                  | 9.1 (6.1–13.6)          | 7.4 (4.8–10.8) | 0.66   |
| Unknown | 1/17                    | 4.4 (0.6–31.5)          | 5.9 (0.1–28.7) | --     |
| Primary tumor radiation therapy |             |                         |         |
| No      | 113/1450                | 6.9 (5.8–8.3)           | 7.8 (6.5–9.3) | Ref    |
| Yes     | 23/206                  | 14.1 (9.3–21.2)         | 11.2 (7.2–16.3) | 0.02   |
| Unknown | 8/106                   | 6.7 (3.3–13.3)          | 7.5 (3.3–14.3) | --     |

(Continued)
analysis. Baseline characteristics of the entire study cohort are outlined in Table 1. The majority of the patients were >65 years of age (59.0%), male (77.5%), and white (90.5%). The predominant histologic subtype was urothelial, representing 86.5% of cases. Most patients (63.3%) had localized disease (T2–T4, N0, M0) at the time of cancer diagnosis. Node-positive (any T, N1–N3, M0) and metastatic disease (any T, any N, M1) accounted for 14.6% and 22.1%, respectively. The median number of cycles of first-line chemotherapy was four.

### Incidence of venous thromboembolism and first-line chemotherapy

The cumulative incidence of VTE in patients who received chemotherapy was 9.6% (95% CI: 8.1–11.3%). Unadjusted absolute, cumulative VTE incidence rates based on first-line chemotherapy regimen are shown in Table 2. The absolute cumulative incidence over time for each chemotherapy regimen is shown in Figure 2. The highest absolute cumulative VTE incidence was seen in patients who received GC at 11.0% (95% CI: 8.2–14.2%). Gemcitabine and carboplatin and cisplatin-containing regimens accounted for an absolute cumulative incidence of VTE of 9.8% (95% CI: 6.9–13.5%) and 6.9% (95% CI: 3.8–11.4%), respectively. Patients who did not receive chemotherapy had an absolute VTE incidence rate of 3.2% (95% CI: 1.7–5.5%).

### Multivariate analysis of venous thromboembolism risk

In addition to chemotherapy treatment group and statistically significant variables in the univariate analysis, age, gender, and race were included as demographic variables in the multivariate model. CVD or CVD risk factors (SHR: 2.27; 95% CI 1.49–3.45, \( P = 0.001 \)), moderate to severe renal dysfunction (SHR: 2.12; 95% CI 1.26–3.59, \( P = 0.005 \)), and non-urothelial histology (SHR: 2.67; 95% CI: 1.72–4.16, \( P < 0.001 \)) were associated with an increased risk of VTE (Table 3). Patients who were treated with radiation therapy to the primary
tumor did not have a statistically significantly greater VTE risk in the multivariate model (SHR: 1.42; 95% CI: 0.83–2.41, \( P = 0.20 \)). Using GC as the reference, there was no statistically significant difference in VTE incidence rates based on chemotherapy regimen. However, patients who did not receive systemic chemotherapy had a decreased incidence of VTE compared to those treated with GC (SHR: 0.32; 95% CI: 0.16–0.61, \( P = 0.001 \)).

### Survival

There was a statistically significant increase in mortality in patients who had a VTE compared to patients without a VTE (\( P < 0.001 \)). Median survival was 6.0 months (95% CI: 3.1–8.8) from time of VTE versus 10.2 months (95% CI: 8.4–12.2) in matched controls (Fig. 3).

### Discussion

Few studies have examined the VTE incidence rate of patients with metastatic UC/VH. A Dutch population-based study demonstrated a 6-month VTE incidence rate of 3.1% in bladder or ureteral cancer patients with distant metastases [17]. Recently, Sandhu et al. found a 6.3% 2-year cumulative VTE incidence rate in patients with advanced bladder cancer utilizing a state cancer registry that was linked to hospital discharge data [18]. In our patient cohort, metastatic UC/VH patients had higher cumulative and 6-month VTE incidence rates, 8.2% and 5.1% respectively, than these previous studies. Importantly, the VTE rate seen in our analysis is comparable to the most thrombogenic primary tumor sites. When compared to the VTE rate (expressed in VTEs per 1000 person-years) in a systematic review and meta-analysis of 8 cancer types from 38 studies, the rate in our cohort (75/1000 person-years) was only superseded by the VTE rate in
pancreatic (102/1000 person-years) and brain cancer (116/1000 person-years) [6]. Consequently, our study supports considering patients with metastatic UC/VH at relatively high risk for VTE.

Venous thromboembolism has been shown to be independently associated with worse overall survival in cancer patients when compared to cancer patients without a VTE. Sørensen et al. reported a 1-year overall survival of 12% in cancer patients with VTE compared to 36% in matched control cancer patients across a wide range of malignancies [3]. Furthermore, other studies, not specifically in UC/VH, have demonstrated that prognosis is worse irrespective of cancer grade or stage [19, 20]. Accordingly, the inferior overall survival in metastatic UC/VH patients who had a VTE compared to those who did not in our analysis is consistent with prior studies, and identification of appropriate preventative interventions that may improve outcomes is imperative.

Currently, based on randomized controlled data, routine primary prophylaxis is not recommended in the outpatient oncology setting with the exception of multiple myeloma patients on lenalidomide- or thalidomide-containing regimens [21]. One reason for this recommendation is the relatively low frequency of VTEs seen in randomized control trials (RCTs). Two primary prophylaxis RCTs, PROTECHT and SAVE-ONCO, demonstrated a statistically significant decrease in VTE in multiple solid tumors [13, 22]. However, the placebo arms in PROTECHT and SAVE-ONCO had a VTE rate of only 2.9% and 3.4%, respectively, at a median duration of treatment of approximately 3.5 months. Therefore, the absolute reduction in VTE was too small to justify primary prophylaxis. The absolute incidence in our study (3.4% at 3 months) is similar to the rates seen in PROTECHT and SAVE-ONCO, thus it is logical to conclude that primary prophylaxis of all patients with metastatic UC/VH would not be recommended.

We evaluated multiple clinical characteristics to identify a subset of metastatic UC/VH patients who might be at particularly high risk for VTE. An association was found between patients with non-urothelial histology, renal dysfunction, or CVD or CVD risk factors and VTE. However, the underlying mechanism of these associations has not been clearly elucidated. It is likely that non-urothelial histology results in more VTEs, at least in part, because patients tend to present with more locally advanced disease when compared to urothelial histology, leading to extrinsic compression of the vasculature and venous thrombosis [23]. Several large, epidemiologic studies have shown a link between CVD or CVD risk factors and renal dysfunction with venous clot formation in noncancer patients [24–26]. Patients with CVD or CVD risk factors and/or renal dysfunction may be predisposed to VTE through alterations in the balance of hemostatic proteins. A recent case–control study suggested that chronic kidney disease patients with a VTE had increased levels of Factor VIII and von Willebrand factor [27]. Additionally, patients with coronary artery disease and peripheral arterial disease have been shown to have elevated markers of coagulation, such as fibrinogen and D-dimer, though correlation with VTE rates were not assessed in these studies [28, 29]. We believe that the association of VTE with these clinical characteristics has merit, but our findings require validation in an independent cohort. If validated as risk factors, these features may be used in the future to identify a patient population with sufficiently high VTE risk for a primary prophylaxis study.

Numerous studies have suggested that cisplatin increases VTE risk [7–9]. Recently, the combination of GC has been associated with especially high VTE rates. Plimack et al. presented a vascular (arterial and venous) event rate of 23% in a neoadjuvant study of dose-dense GC for muscle-invasive bladder cancer, leading to early study closure [30]. Thus, we were interested in comparing the VTE rates for GC to other chemotherapy regimens in patients with metastatic UC/VH. In our patient cohort, there was no statistical difference in VTE risk based on chemotherapy group when compared to GC. However, our result may represent a false negative as the analysis was underpowered to detect a small difference. Interestingly, though not statistically significant, the absolute VTE incidence rate was highest in the patients that were treated with GC, with an 11.0% VTE rate. Conversely, patients treated with cisplatin regimens, which did not include gemcitabine, had a VTE rate of 6.9%. Moreover, the point estimates of the subdistribution hazard ratios for each of the chemotherapy groups in the multivariate analysis were <1 when compared to GC. This suggests the possibility of gemcitabine increasing VTE risk or a synergistic effect in patients treated with GC. The decreased incidence of VTE seen in patients who did not receive chemotherapy may support the role of cytotoxic chemotherapy as a risk factor for VTE. However, this result should be interpreted with caution. Patients who did not receive chemotherapy may have had less intensive surveillance imaging, since there was no reason to ascertain treatment response, thereby missing incidental pulmonary emboli.

There are several limitations to our analysis. First, our study is limited by the inherent confounders and biases associated with any retrospective analysis. Second, whether a VTE was catheter associated was not consistently captured and therefore not included in the analysis. Also, data were not available on whether patients were already on anticoagulation for an alternative indication (e.g., atrial fibrillation). Furthermore, some of the clinical factors were
investigator designated (e.g., moderate to severe renal dysfunction, diabetes, or hypertension) as opposed to utilizing established criteria for diagnosis of these conditions. We also did not have the percentages of each histologic subtype composing tumors of mixed histologies; therefore, we categorized patients based on the predominant histologic pattern. Finally, during the era in which the data were captured, clinical trials including agents that may increase VTE rates (e.g., bevacizumab, cetuximab) were ongoing and trial participants were not excluded from this analysis [10, 11].

Based on our results, patients with metastatic UC/VH should be counseled about their risk of VTE and the associated clinical signs and symptoms. Patients with significantly increased risk should be considered for primary prophylaxis in clinical trials designed to enroll a high-risk population. Additionally, larger population-based studies should be undertaken to validate the clinical risk factors identified in this analysis and further evaluate the impact of chemotherapy regimens on VTE risk. Finally, more intensive investigation of the underlying biologic mechanisms is necessary to improve our understanding of the pathogenesis of cancer-associated thrombosis and identification of novel biomarkers to improve VTE risk stratification.

**Conflict of Interest**

None declared.

**References**

1. Timp, J. F., S. K. Braekkan, H. H. Versteeg, and S. C. Cannegieter. 2013. Epidemiology of cancer-associated venous thrombosis. Blood 122:1712–1723.
2. Lee, A. Y., and E. A. Peterson. 2013. Treatment of cancer-associated thrombosis. Blood 122:2310–2317.
3. Sorensen, H. T., L. Mellemkjaer, J. H. Olsen, and J. A. Baron. 2000. Prognosis of cancers associated with venous thromboembolism. N. Engl. J. Med. 343:1846–1850.
4. Prandoni, P., A. W. Lensing, A. Piccioli, E. Bernardi, P. Simioni, B. Girolami, et al. 2002. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484–3488.
5. Khorana, A. A., N. M. Kuderer, E. Culakova, G. H. Lyman, and C. W. Francis. 2008. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 111:4902–4907.
6. Horsted, F., J. West, and M. J. Grainge. 2012. Risk of venous thromboembolism in patients with cancer: a systematic review and meta-analysis. PLoS Med. 9:e1001275.
7. Moore, R. A., N. Adel, E. Riedel, M. Bhutani, D. R. Feldman, N. E. Tabbara, et al. 2011. High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis. J. Clin. Oncol. 29:3466–3473.
8. Seng, S., Z. Liu, S. K. Chiu, G. Sonpavde, T. K. Choueiri, C. K. Tsao, et al. 2012. Risk of venous thromboembolism in patients with cancer treated with Cisplatin: a systematic review and meta-analysis. J. Clin. Oncol. 30:4416–4426.
9. Starling, N., S. Rao, D. Cunningham, T. Iveson, M. Nicolson, F. Coxon, et al. 2009. Thromboembolism in patients with advanced gastrointestinal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group. J. Clin. Oncol. 27:3786–3793.
10. Hahn, N. M., W. M. Stadler, R. T. Zon, D. Waterhouse, J. Picus, S. Nattam, et al. 2011. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J. Clin. Oncol. 29:1525–1530.
11. Hussain, M., S. Daignault, N. Agarwal, P. D. Grivas, A. O. Siefker-Radtke, I. Puzanov, et al. 2014. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. Cancer 120:2684–2693.
12. Numico, G., O. Garrone, V. Dongiovanni, N. Silvestris, I. Colantonio, G. Di Costanzo, et al. 2005. Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine. Cancer 103:994–999.
13. Agnelli, G., D. J. George, A. K. Kakkar, W. Fisher, M. R. Lassen, P. Mismetti, et al. 2012. Semuloparin for thromboprophylaxis in patients receiving chemotherapy for cancer. N. Engl. J. Med. 366:601–609.
14. Galsky, M. D., S. K. Pal, S. Chowdhury, L. C. Harshman, S. J. Crabb, Y. N. Wong, et al. 2015. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121:2586–2593.
15. von der Maase, H., S. W. Hansen, J. T. Roberts, L. Dogliotti, T. Oliver, M. J. Moore, et al. 2000. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J. Clin. Oncol. 18:3068–3077.
16. Bajorin, D. F., P. M. Dodd, M. Mazumdar, M. Fazzari, J. A. McCaffrey, H. I. Scher, et al. 1999. Long-term survival in metastatic transitional-cell carcinoma and
prognostic factors predicting outcome of therapy. J. Clin. Oncol. 17:3173–3181.
17. Blom, J. W., J. P. Vanderschoot, M. J. Oostindier, S. Osanto, F. J. van der Meer, and F. R. Rosendaal. 2006. Incidence of venous thrombosis in a large cohort of 66,329 cancer patients: results of a record linkage study. J. Thromb. Haemost. 4:529–535.
18. Sandhu, R., C. X. Pan, T. Wun, D. Harvey, H. Zhou, R. H. White, et al. 2010. The incidence of venous thromboembolism and its effect on survival among patients with primary bladder cancer. Cancer 116:2596–2603.
19. Chew, H. K., T. Wun, D. Harvey, H. Zhou, and R. H. White. 2006. Incidence of venous thromboembolism and its effect on survival among patients with common cancers. Arch. Intern. Med. 166:458–464.
20. Gross, C. P., D. H. Galusha, and H. M. Krumholz. 2007. The impact of venous thromboembolism on risk of death or hemorrhage in older cancer patients. J. Clin. Oncol. 25:3037–3043.
21. Lyman, G. H., A. A. Khourana, N. M. Kuderer, A. Y. Lee, J. I. Arcelus, E. P. Balaban, et al. 2013. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J. Clin. Oncol. 31:2189–2204.
22. Agnelli, G., G. Gussoni, C. Bianchini, M. Verso, M. Mandalà, L. Cavanna, et al. 2009. Nadroparin for the prevention of thromboembolic events in ambulatory patients with metastatic or locally advanced solid cancer receiving chemotherapy: a randomised, placebo-controlled, double-blind study. Lancet Oncol. 10:943–949.
23. Pons, E., A. Orsola, J. Morote, and J. Bellmunt. 2011. Variant forms of bladder cancer: basic considerations on treatment approaches. Curr. Oncol. Rep. 13:216–221.
24. Eliasson, A., D. Bergqvist, M. Bjorck, S. Acosta, N. H. Sternby, and M. Ogren. 2006. Incidence and risk of venous thromboembolism in patients with verified arterial thrombosis: a population study based on 23,796 consecutive autopsies. J. Thromb. Haemost. 4:1897–1902.
25. Mahmoodi, B. K., R. T. Gansevoort, N. J. Veeger, A. G. Matthews, G. Navis, H. L. Hillege, et al. 2009. Microalbuminuria and risk of venous thromboembolism. JAMA 301:1790–1797.
26. Wattanakit, K., M. Cushman, C. Stehman-Breen, S. R. Heckbert, and A. R. Folsom. 2008. Chronic kidney disease increases risk for venous thromboembolism. J. Am. Soc. Nephrol. 19:135–140.
27. Ocak, G., C. Y. Vossen, W. M. Lijfering, M. Verduijn, F. W. Dekker, F. R. Rosendaal, et al. 2014. Role of hemostatic factors on the risk of venous thrombosis in people with impaired kidney function. Circulation 129:683–691.
28. Strano, A., D. Hoppensteadt, J. M. Walenga, J. Fareed, C. Sabbá, E. Berardi, et al. 1996. Plasma levels of the molecular markers of coagulation and fibrinolysis in patients with peripheral arterial disease. Semin. Thromb. Hemost. 22(Suppl 1):35–40.
29. Thompson, S. G., J. Kienast, S. D. Pyke, F. Haverkate, and J. C. van de Loo. 1995. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N. Engl. J. Med. 332:635–641.
30. Plimack, E. R., J. H. Hoffman-Censits, and A. Kutikov, et al. 2014. Neoadjuvant dose-dense gemcitabine and cisplatin (DDGC) in patients (pts) with muscle-invasive bladder cancer (MIBC): Final results of a multicenter phase II study. [abstract] In: American Society of Clinical Oncology (ASCO) Annual Meeting; May 30-June 3, Chicago, IL. Abstract #4513.

Supporting Information

Additional supporting information may be found in the online version of this article:

Table S1. Chemotherapy regimens utilized in each treatment group.
Table S2. Clinical characteristics assessed in univariate analysis for association with VTE risk.